Search

Pholcodine

Pholcodine is not approved in Canada. … [A31742] Pholcodine is not prescribed in the United States where it is classed as a Schedule I drug. It is categorized as Class B drug in the UK and officially taken out of the shelves in 2008.

Bordetella pertussis pertactin antigen (formaldehyde inactivated)

Vanzacaftor

[L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor … It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

Idebenone

Lack of improvement in cognitive function halted its production for these conditions, however it continues to be investigated for use in other conditions associated with mitochondrial damage. … LHON is a mitochondrially inherited degeneration of retinal ganglion cells, resulting in acute central vision loss.

Prucalopride

[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]

Eculizumab

[L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007. … [L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria

Rolapitant

By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.

Foscarnet

An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.

Ustekinumab

L52830] and Wezlana [L52073] in Canada, and Uzpruvo in the EU. … In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults.

Zolmitriptan

[A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment. … It is currently available in both tablet and nasal spray forms.[L12978]